Well, that was a weight off my chest, better out than in, as they say. After Brexit, at least the world will be pulled back into its axis with the election of America’s first woman president and wait a minute, what are you saying? No, that can’t be right he won? Really? REALLY?
And the world turns
OpinionWell, that was a weight off my chest, better out than in, as they say. After Brexit, at least the world will be pulled back into its axis with the election of America’s first woman president and wait a minute, what are you saying? No, that can’t be right he won? Really? REALLY?
Proteros inks US$167m oncology pact with MSD
Latest NewsProteros has expanded its epigenetic drug discovery services for MSD. Just one year after having signed a first R&D pact, the computational chemistry firm inked a second contract in oncology.
Running made by biotech
Latest NewsAdidas has presented the world’s first lightweight racing shoe made by recombinantly produced silk fibers.
Acesion Pharma: New head of finance
AppointmentsPharmaMar: Pushing the borders
AppointmentsBIA: Three new faces on the board
AppointmentsMedigene offers neoantigen-specific TCRs
Latest NewsUntil mid-October, cancer immunotherapy play Medigene AG was a pure drug developer. With a potential US$1bn TCR-contract manufacturing deal with Bluebird Bio, it widened its business focus. Now, the company presented a process that delivers neospecific anti-tumour TCRs.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.
Roche ramps up immunotherapy R&D
Latest NewsSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies.